Skip to content
Screener

Mesa Laboratories MLAB Clinical Genomics — Cost Of Revenue

Other segment segments

Biopharmaceutical Development
$4.48M-13.6%

Similar metrics at other companies

RFL
RFLCost Of Product Revenue — Cost Of Revenue
$8K-11.1%
Forrester Research logo
FORRDirect Costs Of Events — Cost Of Revenue
$7.09M-21.0%
BTCS logo
BTCSBlockchain Infrastructure Revenues — Cost Of Revenue
$1.12M-28.3%
BTCS logo
BTCSDe Fi Revenues — Cost Of Revenue
$9.08K
Taboola.com Ltd. logo
TBLACost Of Revenue
$337.35M+2.3%
SpaceX logo
SPCXCost Of Revenue
$3.5B+53.2%

Other financials

Income statement

See full
Revenue$60.1M+1.0%
Gross profit$31.2M-0.5%
Operating income-$664.0K+85.5%
Net income$2.8M-40.3%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$30.7M+44.3%
Total debt$78.5M-52.9%
Total equity$188.8M+9.4%
Total assets$419.2M-3.8%

Cash flow

See full
Operating cash flow$14.7M+678%
CapEx$559.0K-44.6%
Free cash flow$14.2M+1,504%

Valuation

See full
Market cap$574.42M+72.6%
Enterprise value$622.2M+30.1%
P/E42×
P/S2.3×+0.9×

Profitability

See full
Gross margin56.8%
Operating margin2.3%
Net margin1.5%+0.8pp
FCF margin21.2%+7.3pp

Returns & leverage

See full
Return on equity2.2%+1.1pp
Debt / equity0.4×-0.6×
Current ratio1.8×+1.1×

Where this comes from

Reported directly by Mesa Laboratories in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The source filing: Mesa Laboratories’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 5:17 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0001437749-26-026808
Three months ended June 30, 2026Sterilization and Disinfection ControlBiopharmaceutical DevelopmentCalibration SolutionsClinical GenomicsTotal
Depreciation in cost of revenue43778111119745
Amortization in cost of revenue121379-191691
Other cost of revenue (b)6,7884,0205,1433,73919,690
Total segment cost of revenue7,3464,4775,2544,04921,126
Gross Profit (c)$17,159$7,582$8,031$6,240$39,012
Reconciling items:
Operating expense$31,981
Operating income7,031

Document

FAQ

What is Mesa Laboratories's clinical genomics — cost of revenue?
Mesa Laboratories (MLAB) reported clinical genomics — cost of revenue of $4.05M in Q2 2026.
How has Mesa Laboratories's clinical genomics — cost of revenue changed year-over-year?
Mesa Laboratories's clinical genomics — cost of revenue decreased by 16.9% year-over-year, from $4.87M to $4.05M.
What is the long-term trend for Mesa Laboratories's clinical genomics — cost of revenue?
Over 2 years (2024 to 2026), Mesa Laboratories's clinical genomics — cost of revenue has grown at a -12.9% compound annual growth rate (CAGR), from $25.51M to $19.36M.
What does clinical genomics — cost of revenue mean?
This represents the total direct costs incurred to produce and deliver the products and services sold by the Clinical Genomics segment. It is a primary measure of the segment's direct operational efficiency and production cost structure.

Ask your AI about Mesa Laboratories's clinical genomics — cost of revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude